Actively Recruiting
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
Led by Gene Solutions · Updated on 2025-07-16
200
Participants Needed
1
Research Sites
116 weeks
Total Duration
On this page
Sponsors
G
Gene Solutions
Lead Sponsor
T
The Medical Genetics Institute (MGI) of HCMC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who have undergone K4Care testing
CONDITIONS
Official Title
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological and imaging confirmation of metastatic or progressive stage IV cancer.
- Consent to the use of their clinical data.
- Diagnosis of one of the following common solid tumor types: lung, colorectal, breast, gastric, or cancer of unknown primary origin.
- Prior K4Care testing to identify tumor tissue (FFPE) mutations and consent to the use of their sequencing data.
You will not qualify if you...
- Refusal to participate in the study.
- Absence of prior K4Care testing.
- Diagnosis of early-stage cancer or hematologic malignancy.
- Refusal to provide clinical information or blood samples.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical Genetics Institute
Ho Chi Minh City, Hồ Chí Minh, Vietnam
Actively Recruiting
Research Team
S
Sinh D Nguyen, PhD. MD
CONTACT
L
Lan N Tu, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here